DANCANN PHARMA A/S - Group

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 44.7% 42.5% 3.2% 9.4%  
Credit score (0-100)  0 0 0 56 25  
Credit rating  N/A C C BBB BB  
Credit limit (kDKK)  33.3 -0.0 -0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 874 5,708 6,073  
Gross profit  527 -2,835 -6,494 -5,670 -3,443  
EBITDA  527 -2,835 -6,494 -14,187 -12,894  
EBIT  527 -2,835 -6,494 -16,418 -60,115  
Pre-tax profit (PTP)  -500.0 -4,255.0 -11,750.0 -18,250.0 -62,239.0  
Net earnings  -500.0 -4,255.0 -11,750.0 -16,064.0 -62,260.0  
Pre-tax profit without non-rec. items  527 -2,835 -6,494 -18,250 -62,239  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 9,281 3,936  
Shareholders equity total  0.0 0.0 0.0 62,793 9,506  
Interest-bearing liabilities  0.0 0.0 0.0 7,557 5,913  
Balance sheet total (assets)  0.0 0.0 0.0 73,695 17,394  

Net Debt  0.0 0.0 0.0 -3,194 3,907  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 874 5,708 6,073  
Net sales growth  0.0% 0.0% 0.0% 553.1% 6.4%  
Gross profit  527 -2,835 -6,494 -5,670 -3,443  
Gross profit growth  0.0% 0.0% -129.1% 12.7% 39.3%  
Employees  0 0 0 10 12  
Employee growth %  0.0% 0.0% 0.0% 0.0% 20.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 0 73,695 17,394  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% -76.4%  
Added value  527.0 -2,835.0 -6,494.0 -16,418.0 -12,894.0  
Added value %  0.0% 0.0% -743.0% -287.6% -212.3%  
Investments  0 0 0 54,828 -90,399  

Net sales trend  0.0 0.0 0.0 1.0 2.0  
EBIT trend  1.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% -743.0% -248.5% -212.3%  
EBIT %  0.0% 0.0% -743.0% -287.6% -989.9%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 289.6% 1,746.0%  
Net Earnings %  0.0% 0.0% -1,344.4% -281.4% -1,025.2%  
Profit before depreciation and extraordinary items %  0.0% 0.0% -1,344.4% -242.3% -247.6%  
Pre tax profit less extraordinaries %  0.0% 0.0% -743.0% -319.7% -1,024.8%  
ROA %  0.0% 0.0% 0.0% -20.7% -131.5%  
ROI %  0.0% 0.0% 0.0% -21.6% -139.7%  
ROE %  0.0% 0.0% 0.0% -25.6% -172.2%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 0.0% 85.2% 54.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 191.0% 129.9%  
Relative net indebtedness %  0.0% 0.0% 0.0% 2.6% 96.9%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 22.5% -30.3%  
Gearing %  0.0% 0.0% 0.0% 12.0% 62.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 80.0% 34.6%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 1.5 0.4  
Current Ratio  0.0 0.0 0.0 1.5 0.4  
Cash and cash equivalent  0.0 0.0 0.0 10,751.0 2,006.0  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 103.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 77.8 36.7  
Current assets / Net sales %  0.0% 0.0% 0.0% 285.8% 52.5%  
Net working capital  0.0 0.0 0.0 5,412.0 -4,697.0  
Net working capital %  0.0% 0.0% 0.0% 94.8% -77.3%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 571 506  
Added value / employee  0 0 0 -1,642 -1,075  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -1,419 -1,075  
EBIT / employee  0 0 0 -1,642 -5,010  
Net earnings / employee  0 0 0 -1,606 -5,188